treasures or treasure
US Adds 9th Company to List of Salt Typhoon Telecom VictimsHow co-writing a book threatened the Carters’ marriage
LPL Financial to present at the Goldman Sachs Financial Services Conference
Unwrap the latest AI features with Amazon Fire TabletsJudge weighs whether to order Fani Willis to comply with lawmakers' subpoenas over Trump case
CHICAGO (AP) — Sam Darnold threw for 90 of his 330 yards in overtime to set up Parker Romo's game-ending 29-yard field goal, and the Minnesota Vikings outlasted the Chicago Bears 30-27 on Sunday after giving up 11 points in the final 22 seconds of regulation. Read this article for free: Already have an account? To continue reading, please subscribe: * CHICAGO (AP) — Sam Darnold threw for 90 of his 330 yards in overtime to set up Parker Romo's game-ending 29-yard field goal, and the Minnesota Vikings outlasted the Chicago Bears 30-27 on Sunday after giving up 11 points in the final 22 seconds of regulation. Read unlimited articles for free today: Already have an account? CHICAGO (AP) — Sam Darnold threw for 90 of his 330 yards in overtime to set up Parker Romo’s game-ending 29-yard field goal, and the Minnesota Vikings outlasted the Chicago Bears 30-27 on Sunday after giving up 11 points in the final 22 seconds of regulation. Darnold threw two touchdown passes, Jordan Addison caught eight passes for a career-high 162 yards and a touchdown, and T.J. Hockenson had 114 yards receiving for the Vikings (9-2), who remained one game behind Detroit in the rugged NFC North. Caleb Williams threw for 340 yards and two touchdowns for the Bears (4-7), who lost their fifth straight. Minnesota appeared to have the game in hand, leading 27-16 with 1:56 left after Romo kicked a 26-yard field goal. But the Bears weren’t finished. Deandre Carter made up for a muffed punt that led to a touchdown in the third quarter with a 55-yard kickoff return to the 40. Williams took it from there, capping an eight-play drive with a 1-yard touchdown pass to Keenan Allen. A 2-point conversion pass to DJ Moore made it 27-24 with 22 seconds remaining. The Bears recovered the onside kick and Williams hit Moore over the middle for a 27-yard gain to the 30 before spiking the ball. Cairo Santos made a 48-yard field goal as time expired. Chicago won the coin toss, but Williams was sacked for a 12-yard loss on second down, leading to a three-and-out. The Vikings took over at the 21, and Darnold led a 10-play drive, overcoming a sack and two penalties. Darnold connected with Hockenson for a 29-yard completion that put the ball on the 9. He took a knee and then Romo nailed the winner. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. ___ AP NFL: https://apnews.com/hub/NFL Advertisement AdvertisementNet sales increased 2% versus last year with comparable sales up 1% Operating margin of 9.3% improved 270 basis points versus last year Market share gains across all brands in the quarter Raises outlook for fiscal 2024 net sales, gross margin and operating income growth SAN FRANCISCO , Nov. 21, 2024 /PRNewswire/ -- Gap Inc. GAP , the largest specialty apparel company in the U.S. and a house of iconic brands including Old Navy, Gap, Banana Republic, and Athleta, today reported financial results for its third quarter ended November 2, 2024. "I'm proud that Gap Inc. delivered another successful quarter, growing net sales for the 4 th consecutive quarter and gaining market share across all brands while meaningfully expanding operating margin," said President and Chief Executive Officer, Richard Dickson . "Consistent execution of our strategic priorities, including the rigor and repetition we're applying to our brand reinvigoration playbook, is making us a stronger company and demonstrates our continued progress in unlocking Gap Inc.'s full potential." Dickson continued: "Holiday is off to a strong start and we remain focused on executing with excellence in the fourth quarter. Our performance year-to-date gives us the confidence to raise our full year outlook for sales, gross margin and operating income growth." Third Quarter Fiscal 2024 – Financial Results Net sales of $3.8 billion were up 2% compared to last year. Comparable sales were up 1% year-over-year. Due to the 53 rd week in fiscal 2023, in order to maintain consistency, comparable sales for the third quarter of fiscal 2024 are compared to the 13 weeks ended November 4, 2023 . Store sales decreased 2% compared to last year. The company ended the quarter with 3,603 store locations in about 40 countries, of which 2,544 were company operated. Online sales increased 7% compared to last year and represented 40% of total net sales. Gross margin of 42.7% increased 140 basis points versus last year's gross margin. Merchandise margin increased 90 basis points versus last year primarily driven by improved inventory management. Rent, occupancy, and depreciation (ROD) as a percent of sales leveraged 50 basis points versus last year. Operating expense was $1.3 billion . Operating income was $355 million ; operating margin of 9.3%. The effective tax rate was 24%. Net income of $274 million ; diluted earnings per share of $0.72 . Balance Sheet and Cash Flow Highlights Ended the quarter with cash, cash equivalents and short-term investments of $2.2 billion , an increase of 64% from the prior year. Year-to-date net cash from operating activities was $870 million . Year-to-date free cash flow , defined as net cash from operating activities less purchases of property and equipment, was $540 million . Ending inventory of $2.33 billion was down 2% compared to last year. Capital expenditures were $330 million . Paid a third quarter dividend of $0.15 per share, totaling $57 million. The company's Board of Directors approved a fourth quarter fiscal 2024 dividend of $0.15 per share. Additional information regarding free cash flow, which is a non-GAAP financial measure, is provided at the end of this press release along with a reconciliation of this measure from the most directly comparable GAAP financial measure for the applicable period. Third Quarter Fiscal 2024 – Global Brand Results Comparable Sales Third Quarter 2024 2023 Old Navy — % 1 % Gap 3 % (1) % Banana Republic (1) % (8) % Athleta 5 % (19) % Gap Inc. 1 % (2) % Old Navy: Third quarter net sales of $2.2 billion were up 1% compared to last year. Comparable sales were flat. The brand's continued focus on operational rigor and brand reinvigoration drove solid performance in the quarter, despite lapping tougher compares and facing weather-related headwinds. Gap: Third quarter net sales of $899 million were up 1% compared to last year. Comparable sales were up 3% representing the fourth consecutive quarter of positive comparable sales at the brand. Gap's strong product and marketing execution have helped drive continued momentum and consistent results at the brand. Banana Republic: Third quarter net sales of $469 million were up 2% compared to last year. Comparable sales were down 1%. The brand saw strength in its men's business during the quarter and remains focused on fixing the fundamentals. Athleta: Third quarter net sales of $290 million were up 4% compared to last year. Comparable sales were up 5%. As expected, the brand returned to positive comparable sales in the quarter as its new product and marketing are resonating with customers. Fiscal 2024 Outlook As a result of its strong third quarter results, the company is raising its full year outlook for net sales, gross margin and operating income growth compared to prior expectations. Please note that the company's projected full year fiscal 2024 operating income growth below is provided in comparison to its full year fiscal 2023 adjusted operating income, which excludes $93 million in restructuring costs and a $47 million gain on sale of a building. Full Year Fiscal 2024 Current FY24 Outlook Prior FY24 Outlook FY23 Results Net sales Up 1.5% to 2.0% on a 52-week basis Up slightly on a 52-week basis $14.9 billion 1 Gross margin Approximately 220 bps expansion Approximately 200 bps expansion 38.8 % Operating expense Approximately $5.1 billion Approximately $5.1 billion $5.17 billion (adjusted) 2 Operating income Mid to High 60% growth range Mid to High 50% growth range $606 million (adjusted) 3 Effective tax rate Approximately 26.5% Approximately 28% 9.7 % Capital expenditures Approximately $500 million Approximately $500 million $420 million 1 Fiscal year 2023 consisted of 53 weeks and the extra week drove approximately $160 million of incremental sales. 2 Fiscal year 2023 adjusted operating expense of $5.17 billion excludes $89 million in restructuring costs and a $47 million gain on sale. 3 Fiscal year 2023 adjusted operating income of $606 million excludes $93 million in restructuring costs and a $47 million gain on sale. Webcast and Conference Call Information Whitney Notaro , Head of Investor Relations at Gap Inc., will host a conference call to review the company's third quarter fiscal 2024 results beginning at approximately 2:00 p.m. Pacific Time today. Ms. Notaro will be joined by President and Chief Executive Officer, Richard Dickson and Chief Financial Officer, Katrina O'Connell . A live webcast of the conference call and accompanying materials will be available online at investors.gapinc.com . A replay of the webcast will be available at the same location. Non-GAAP Disclosure This press release and related conference call include financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP) and are therefore referred to as non-GAAP financial measures. The non-GAAP measures described below are intended to provide investors with additional useful information about the company's financial performance, to enhance the overall understanding of its past performance and future prospects, and to allow for greater transparency with respect to important metrics used by management for financial and operating decision-making. The company presents these non-GAAP financial measures to assist investors in seeing its financial performance from management's view and because it believes they provide an additional tool for investors to use in computing the company's core financial performance over multiple periods with other companies in its industry. Additional information regarding the intended use of non-GAAP measures included in this press release and related conference call is provided in the tables to this press release. The non-GAAP measures included in this press release and related conference call are adjusted operating expense/adjusted SG&A, adjusted operating income, adjusted operating margin, adjusted diluted earnings per share, and free cash flow. These non-GAAP measures exclude the impact of certain items that are set forth in the tables to this press release. In addition, the company's outlook includes projected full year fiscal 2024 operating income growth compared to its full year fiscal 2023 adjusted operating income. The non-GAAP measures used by the company should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP and may not be the same as similarly titled measures used by other companies due to possible differences in method and in items or events being adjusted. The company urges investors to review the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures included in the tables to this press release below, and not to rely on any single financial measure to evaluate its business. The non-GAAP financial measures used by the company have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. Forward-Looking Statements This press release and related conference call and accompanying materials contain forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than those that are purely historical are forward-looking statements. Words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," "project," and similar expressions also identify forward-looking statements. Forward-looking statements include statements regarding the following: becoming a high performing company; unlocking Gap Inc.'s potential; our four strategic priorities, including maintaining and delivering financial and operational rigor, the reinvigoration of our brands, strengthening our operating platform, and energizing our culture; driving relevance and revenue by executing on our brand reinvigoration playbook; expectations for Old Navy for the holiday season; accelerating Old Navy's presence in the Active category; Old Navy's holiday activations and product; reigniting Gap brand's leadership in trend-right products and creative expression through big ideas and culturally relevant messaging; reestablishing Banana Republic to thrive in the premium lifestyle space; evolving Banana Republic's assortment and fit; continuing to fix the fundamentals at Banana Republic; Banana Republic's holiday product; Athleta's trajectory; Athleta's holiday product; enhancing Athleta's in-store and online experiences; driving high-performance across our teams; executing with excellence; Gap Inc.'s positioning going into the holiday season; expectations for our full year performance; expected year-end inventory levels; expected full year fiscal 2024 net sales; the expected impact of the loss of the 53rd week on full year fiscal 2024 net sales; expected fourth quarter fiscal 2024 net sales; the expected impacts of the loss of the 53rd week and the weekly calendar shift on fourth quarter fiscal 2024 net sales; expected full year fiscal 2024 gross margin; the expected impacts of commodity costs and better inventory management on full year fiscal 2024 gross margin; expected full year fiscal 2024 ROD; expected fourth quarter fiscal 2024 gross margin; the expected impact of the loss of the 53rd week on fourth quarter fiscal 2024 gross margin; expected full year fiscal 2024 SG&A/operating expense; continuing cost discipline and unlocking more efficiencies in the business; expected full year fiscal 2024 operating income; expected full year fiscal 2024 effective tax rate; expected full year fiscal 2024 capital expenditures; generating sustainable, profitable growth and delivering long-term shareholder value; and our dividend policy. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause our actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the following risks, any of which could have an adverse effect on our business, financial condition, results of operations, or reputation: the overall global economic and geopolitical environment, including the ongoing Russia - Ukraine and Israel-Hamas conflicts and recent elections in the United States , and impacts on consumer spending patterns; social and political unrest in our sourcing countries, including Bangladesh , and disruptions to global trade and shipping capacity, including in the Red Sea; the risk that we or our franchisees may be unsuccessful in gauging apparel trends and changing consumer preferences or responding with sufficient lead time; the highly competitive nature of our business in the United States and internationally; the risk that we may be unable to manage our inventory effectively and the resulting impact on our gross margins and sales; the risk that our investments in customer, digital, and omni-channel shopping initiatives may not deliver the results we anticipate; the risk that we fail to maintain, enhance, and protect our brand image and reputation; the risk of loss or theft of assets, including inventory shortage; the risk that we fail to manage key executive succession and retention or continue to attract qualified personnel; reductions in income and cash flow from our credit card arrangement related to our private label and co-branded credit cards; the risk that changes in our business strategy or restructuring our operations may not generate the intended benefits or projected cost savings; the risk that trade matters could increase the cost or reduce the supply of apparel available to us; the risks to our business, including our costs and global supply chain, associated with global sourcing and manufacturing; the risks to our reputation or operations associated with importing merchandise from foreign countries, including failure of our vendors to adhere to our Code of Vendor Conduct; the risk that we or our franchisees may be unsuccessful in identifying, negotiating, and securing new store locations and renewing, modifying, or terminating leases for existing store locations effectively; engaging in or seeking to engage in strategic transactions that are subject to various risks and uncertainties; the risk that our efforts to expand internationally may not be successful; the risk that our franchisees and licensees could impair the value of our brands; the risk of data or other security breaches or vulnerabilities that may result in increased costs, violations of law, significant legal and financial exposure, and a loss of confidence in our security measures; the risk that failures of, or updates or changes to, our IT systems may disrupt our operations; the risk that our comparable sales and margins may experience fluctuations, that we may fail to meet financial market expectations, or that the seasonality of our business may experience fluctuations; the risk of foreign currency exchange rate fluctuations; the risk that our level of indebtedness may impact our ability to operate and expand our business; the risk that we and our subsidiaries may be unable to meet our obligations under our indebtedness agreements; the risk that changes in our credit profile or deterioration in market conditions may limit our access to the capital markets; natural disasters, public health crises (such as pandemics and epidemics), political crises (such as the ongoing Russia - Ukraine and Israel-Hamas conflicts), negative global climate patterns, or other catastrophic events; evolving regulations and expectations with respect to ESG matters, including climate reporting; the adverse effects of climate change on our operations and those of our franchisees, vendors, and other business partners; our failure to comply with applicable laws and regulations and changes in the regulatory or administrative landscape; the risk that we will not be successful in defending various proceedings, lawsuits, disputes, and claims; the risk that our estimates and assumptions used when preparing our financial information are inaccurate or may change; the risk that changes in the geographic mix and level of income or losses, the expected or actual outcome of audits, changes in deferred tax valuation allowances, and new legislation could impact our effective tax rate, or that we may be required to pay amounts in excess of established tax liabilities; the risk that changes in our business structure, our performance or our industry could result in reductions in our pre-tax income or utilization of existing tax carryforwards in future periods, and require additional deferred tax valuation allowances; the risk that the adoption of new accounting pronouncements will impact future results; and the risk that additional information may arise during our close process or as a result of subsequent events that would require us to make adjustments to our financial information. Additional information regarding factors that could cause results to differ can be found in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19, 2024 , as well as our subsequent filings with the Securities and Exchange Commission. These forward-looking statements are based on information as of November 21, 2024 . We assume no obligation to publicly update or revise our forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. About Gap Inc. Gap Inc., a house of iconic brands, is the largest specialty apparel company in America. Its Old Navy , Gap , Banana Republic , and Athleta brands offer clothing, accessories, and lifestyle products for men, women and children. Since 1969, Gap Inc. has created products and experiences that shape culture, while doing right by employees, communities and the planet. Gap Inc. products are available worldwide through company-operated stores, franchise stores, and e-commerce sites. Fiscal year 2023 net sales were $14.9 billion . For more information, please visit www.gapinc.com . Investor Relations Contact: Nina Bari Investor_relations@gap.com Media Relations Contact: Megan Foote Press@gap.com The Gap, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS UNAUDITED ($ in millions) November 2, 2024 October 28, 2023 ASSETS Current assets: Cash and cash equivalents $ 1,969 $ 1,351 Short-term investments 250 — Merchandise inventory 2,331 2,377 Other current assets 580 646 Total current assets 5,130 4,374 Property and equipment, net of accumulated depreciation 2,546 2,552 Operating lease assets 3,217 3,200 Other long-term assets 960 926 Total assets $ 11,853 $ 11,052 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,523 $ 1,433 Accrued expenses and other current liabilities 1,135 1,078 Current portion of operating lease liabilities 617 604 Income taxes payable 50 24 Total current liabilities 3,325 3,139 Long-term liabilities: Long-term debt 1,489 1,488 Long-term operating lease liabilities 3,360 3,456 Other long-term liabilities 544 509 Total long-term liabilities 5,393 5,453 Total stockholders' equity 3,135 2,460 Total liabilities and stockholders' equity $ 11,853 $ 11,052 The Gap, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED 13 Weeks Ended 39 Weeks Ended ($ and shares in millions except per share amounts) November 2, 2024 October 28, 2023 November 2, 2024 October 28, 2023 Net sales $ 3,829 $ 3,767 $ 10,937 $ 10,591 Cost of goods sold and occupancy expenses 2,194 2,211 6,322 6,488 Gross profit 1,635 1,556 4,615 4,103 Operating expenses 1,280 1,306 3,762 3,757 Operating income 355 250 853 346 Interest, net (6) — (12) 8 Income before income taxes 361 250 865 338 Income tax expense 87 32 227 21 Net income $ 274 $ 218 $ 638 $ 317 Weighted-average number of shares - basic 377 371 376 369 Weighted-average number of shares - diluted 383 375 383 373 Earnings per share - basic $ 0.73 $ 0.59 $ 1.70 $ 0.86 Earnings per share - diluted $ 0.72 $ 0.58 $ 1.67 $ 0.85 The Gap, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED 39 Weeks Ended ($ in millions) November 2, 2024 (a) October 28, 2023 (a) Cash flows from operating activities: Net income $ 638 $ 317 Depreciation and amortization 371 394 Gain on sale of building — (47) Change in merchandise inventory (344) (5) Change in accounts payable 156 133 Other, net 49 40 Net cash provided by operating activities 870 832 Cash flows from investing activities: Purchases of property and equipment (330) (288) Net proceeds from sale of building — 76 Purchases of short-term investments (343) — Proceeds from sales and maturities of short-term investments 97 — Net proceeds from divestiture activity, net of cash paid — 9 Net cash used for investing activities (576) (203) Cash flows from financing activities: Repayments of revolving credit facility — (350) Proceeds from issuances under share-based compensation plans 27 18 Withholding tax payments related to vesting of stock units (48) (16) Cash dividends paid (169) (166) Other (3) (2) Net cash used for financing activities (193) (516) Effect of foreign exchange rate fluctuations on cash, cash equivalents, and restricted cash (4) (7) Net increase in cash, cash equivalents, and restricted cash 97 106 Cash, cash equivalents, and restricted cash at beginning of period 1,901 1,273 Cash, cash equivalents, and restricted cash at end of period $ 1,998 $ 1,379 ____________________ (a) For the thirty-nine weeks ended November 2, 2024 and October 28, 2023, total cash, cash equivalents, and restricted cash includes $29 million and $28 million, respectively, of restricted cash recorded within other long-term assets on the Condensed Consolidated Balance Sheets. The Gap, Inc. NON-GAAP FINANCIAL MEASURES UNAUDITED FREE CASH FLOW Free cash flow is a non-GAAP financial measure. We believe free cash flow is an important metric because it represents a measure of how much cash a company has available for discretionary and non-discretionary items after the deduction of capital expenditures. We require regular capital expenditures including technology improvements as well as building and maintaining our stores and distribution centers. We use this metric internally, as we believe our sustained ability to generate free cash flow is an important driver of value creation. However, this non-GAAP financial measure is not intended to supersede or replace our GAAP results. 39 Weeks Ended ($ in millions) November 2, 2024 October 28, 2023 Net cash provided by operating activities $ 870 $ 832 Less: Purchases of property and equipment (330) (288) Free cash flow $ 540 $ 544 The Gap, Inc. NON-GAAP FINANCIAL MEASURES UNAUDITED ADJUSTED STATEMENT OF OPERATIONS METRICS FOR THE THIRD QUARTER OF FISCAL YEAR 2023 The following adjusted statement of operations metrics are non-GAAP financial measures. These measures are provided to enhance visibility into the Company's underlying results for the period excluding the impact of restructuring costs. Management believes the adjusted metrics are useful for the assessment of ongoing operations as we believe the adjusted items are not indicative of our ongoing operations, and provide additional information to investors to facilitate the comparison of results, on an annualized basis, against past and future years. However, these non-GAAP financial measures are not intended to supersede or replace the GAAP measures. Operating Expenses Operating Expenses as a % of Net Sales (b) Operating Income Operating Margin (b) Income Tax Expense Net Income Earnings per Share - Diluted ($ in millions) 13 Weeks Ended October 28, 2023 GAAP metrics, as reported $ 1,306 34.7 % $ 250 6.6 % $ 32 $ 218 $ 0.58 Adjustments for: Restructuring costs (a) (5) (0.1) % 5 0.1 % 2 3 0.01 Non-GAAP metrics $ 1,301 34.5 % $ 255 6.8 % $ 34 $ 221 $ 0.59 ____________________ (a) Primarily represents consulting and other associated costs related to our previously announced actions to further simplify and optimize our operating model and structure. (b) Metrics were computed individually for each line item; therefore, the sum of the individual lines may not equal the total. The Gap, Inc. NET SALES RESULTS UNAUDITED The following table details the Company's third quarter fiscal year 2024 and 2023 net sales (unaudited): ($ in millions) Old Navy Global Gap Global Banana Republic Global Athleta Global Other (2) Total 13 Weeks Ended November 2, 2024 U.S. (1) $ 1,949 $ 683 $ 406 $ 281 $ 21 $ 3,340 Canada 190 95 43 9 — 337 Other regions 11 121 20 — — 152 Total $ 2,150 $ 899 $ 469 $ 290 $ 21 $ 3,829 ($ in millions) Old Navy Global Gap Global Banana Republic Global Athleta Global Other (2) Total 13 Weeks Ended October 28, 2023 U.S. (1) $ 1,917 $ 664 $ 398 $ 267 $ 15 $ 3,261 Canada 193 96 42 10 — 341 Other regions 16 127 20 2 — 165 Total $ 2,126 $ 887 $ 460 $ 279 $ 15 $ 3,767 ____________________ (1) U.S. includes the United States and Puerto Rico. (2) Primarily consists of net sales from revenue-generating strategic initiatives. The Gap, Inc. REAL ESTATE Store count, openings, closings, and square footage for our stores are as follows: February 3, 2024 39 Weeks Ended November 2, 2024 November 2, 2024 Number of Store Locations Number of Stores Opened Number of Stores Closed Number of Store Locations Square Footage (in millions) Old Navy North America 1,243 19 7 1,255 19.9 Gap North America 472 3 14 461 4.9 Gap Asia 134 — 9 125 1.1 Banana Republic North America 400 3 10 393 3.3 Banana Republic Asia 43 2 5 40 0.1 Athleta North America 270 2 2 270 1.1 Company-operated stores total 2,562 29 47 2,544 30.4 Franchise 998 121 60 1,059 N/A Total 3,560 150 107 3,603 30.4 View original content to download multimedia: https://www.prnewswire.com/news-releases/gap-inc-reports-third-quarter-fiscal-2024-results-raises-full-year-outlook-302313560.html SOURCE Gap Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
An upcoming hearing at The Supreme Court, which will decide if survivors of domestic violence are able to sue their abusers for “family violence,” could result in consequences for survivors, warns one legal advocacy non-profit. In February, 2025, Canada’s Supreme Court will decide if family violence is recognized as a tort – a civil wrong, for which someone could be held liable. If recognized, the decision would allow for family court cases over family violence, giving survivors of domestic violence the option to sue their abusers for family violence. But the National Association of Women and the Law (NAWL), which is set to appear before the Supreme Court alongside other organizations and stakeholders to present the implications of the decision, is concerned the new tort could give abusers an avenue to sue their victims. “Often, what we see is abusers using remedies that are meant for survivors and kind of twisting them and using them to their advantage,” said Suzanne Zaccour, director of legal affairs at NAWL, in an interview with rabble.ca . “We think abusers may try to use this tort of family violence to sue their own victims.” How parental alienation arguments target survivors Zaccour’s main concern is the argument of parental alienation, a tactic that is increasingly used in custody battles in Canadian courtrooms. The argument is often used by abusers in family court cases when a woman alleges their partner is abusive, Zaccour explained. Sometimes, the abusive party will claim that the other party has been psychologically manipulating their child and turning them against them by repeatedly badmouthing them to their child or falsely accusing them of abuse. In some cases, if the court believes allegations of abuse were falsified to alienate a child from their parent, abusers can be awarded custody of their children. A UN report , released this summer, called the concept “highly gendered”, “unfounded and unscientific”, highlighting that it is “predominantly used against mothers”. Zaccour worries that if the Supreme Court decides to recognize a tort of family violence, abusers will be able to argue that parental alienation is family violence – and that this could force victims to pay damages to their abusers. “We’re seeing that courts are already imposing costs on survivors, taking kids away from them,” Zaccour said. “We think it is likely that courts could also make them pay damages.” “They’re going to say ‘well, my ex alienated the children’ if their children don’t want to see them because they’re violent,” Zaccor explained. “They’re going to say ‘this constitutes family violence, so, she needs to pay me.’” What safeguards are needed NAWL is supportive of recognizing family violence as a tort that can be used in family court – but only with appropriate safeguards. Zaccour hopes that their intervention at the Supreme Court will highlight the implications of the decision and result in protections for survivors being written in. “We’re hoping to inform the court of these risks and, ultimately, make sure that there are some safeguards in the decision,” she said, “to encourage them if they decide to recognize this tort that they do so carefully, making sure judges are instructed appropriately.” Still, Zaccour thinks there is a simpler solution – banning the concept of parental alienation from family court altogether. “They need to legislate that you cannot use this unscientific theory in court cases,” she said. In January, a coalition of over 250 Canadian feminist organizations, including NAWL, sent letters to Prime Minister Justin Trudeau and Minister of Justice Arif Viranion, urging the government to remove the concept from family law cases. The concept has yet to be removed. Zaccour warned that, if not removed, the concept will continue to be used as a strategy to further target survivors of domestic violence, both in custody battles and in future family violence cases, should the tort be recognized. “If the government doesn’t act, abusers will continue to use this,” she said. “We have to make sure that women don’t face even more consequences.” Support rabble today! We’re so glad you stopped by! Thanks for consuming rabble content this year. rabble.ca is 100% reader and donor funded, so as an avid reader of our content, we hope you will consider gifting rabble with a donation during our summer fundraiser today. Nick Seebruch, editor Whether it be a one-time donation or a small monthly contribution, your support is critical to keep rabble writers producing the work you’ve come to rely on as a part of a healthy media diet. Become a rabble rouser — donate to rabble.ca today. Nick Seebruch, editor Support rabble.ca
SIMMONS SAYS: Alexander Ovechkin's chase of Great One an uncomfortable collision of sports and politics
Phoenix, AZ, Dec. 27, 2024 (GLOBE NEWSWIRE) -- The American College of Medical Toxicology (ACMT) is pleased to announce its 2025 Annual Scientific Meeting (#ACMT2025) and Symposia on April 2 - 6 at the Fairmont Hotel in Vancouver, Canada. This five-day program featuring three pre-meeting activities in addition to the main conference, will expose attendees to the latest advancements in medical toxicology research, and offer numerous opportunities for networking and engagement throughout. Registration is open for all activities, with early bird savings rates active until Fri day, February 21st . Continuing medical, nursing, and pharmacy education credits are available. The program will commence on Wednesday, April 2nd, with a half-day symposium titled "Thalli--Ummmm, Was This a Murder? " organized by the American Academy of Clinical Toxicology (AACT). This symposium will explore the clinical and forensic complexities of thallium poisoning, emphasizing timely access to antidotes and the nuances of patient care while also examining analytical testing, effective media communication, and expert witness testimony. On Thursday, April 3rd, ACMT will host two, innovative, full-day activities concurrently : The ACMT Symposium “Harm Reduction and the Management of Substance Use Disorder (SUD)” will bring together medical experts, researchers, and advocates to explore harm reduction strategies across diverse settings and recovery stages. Vancouver’s pioneering role in harm reduction makes it an ideal location for this symposium, which will explore the latest evidence, ethical considerations, and practical applications of harm reduction strategies. This program will feature keynote lectures from three renowned experts in harm reduction. The program will open with the Medical Toxicology Foundation’s Donovan Keynote lecture with Daniel Ciccarone, MD MPH, an addiction medicine researcher from the University of California, San Francisco. The lecture will cover the evolving challenges of polysubstance use, the rise of fentanyl and its analogs, and its impact on mortality, morbidity, and harm reduction. Drawing on the expertise of local professionals on the frontlines of Vancouver’s public health policies and programs, ACMT is pleased to welcome Patricia Daly, MD, Chief Medical Health Officer for Vancouver Coastal Health. Dr. Daly’s keynote will address the politics and history of harm reduction in Vancouver, including successes and challenges. The third keynote lecture will feature Guy Felicella , a native of the Vancouver area, and a passionate advocate and speaker who overcame addiction and homelessness to inspire recovery and reduce stigma. Drawing on his lived experience, he will provide insights into harm reduction and recovery in Vancouver’s downtown eastside. ACMT will also offer an “Occupational & Environmental Toxicology Boot Camp” on Thursday, April 3rd. This full-day symposium aims to address a crucial gap in toxicology education by focusing on occupational and environmental toxicology. Led by expert medical toxicologists who are also certified in Occupational and Environmental Medicine (OEM), the boot camp targets practicing toxicologists, recent grads, fellows in training, and others interested in occupational and environmental toxicology seeking to enhance their knowledge in this field. Through a comprehensive curriculum, attendees will dive into a variety of topics with emphasis on regulatory toxicology, risk assessment, pulmonary toxicology, reproductive toxicology, as well as irritant gasses, organic pollutants, and heavy metals. The 2025 ACMT Annual Scientific Meeting will run from Friday, April 4th through Sunday, April 6th. Attendees will be exposed to cutting-edge research through a variety of educational engaging plenary sessions. Lectures will cover topics in Environmental & Public Health, Research, Addiction Toxicology, Professional Development, and New Insights in Toxicology. Topics include: The Toxicologic Impact of War on the Environment: Lessons from the Field in Ukraine The Wild West of Ketamine: Safety & Health Equity Concerns Surrounding the Use of Ketamine for Psychiatric Conditions Planetary Toxicology and Climate Change Microplastic Pollution: An Emerging Toxicologic Exposure of Public Health Concern Late Breaking Topic: The End of Fluoridation? Emerging Treatments for Snake Envenomation MOUD in Corrections: Lessons from a Mega-Jail Strategies to Increase Diversity, Equity & Inclusion in Medical Toxicology There will be several collaborative panel sessions featuring the latest developments in toxicology from around the world. These sessions will feature representatives of The American Academy of Clinical Toxicology (AACT), the American Society of Addiction Medicine (ASAM), the National Institute on Drug Abuse (NIDA), Middle East & North Africa Clinical Toxicology Association (MENATOX), Asia Pacific Association of Medical Toxicology (APAMT), the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), and Red de Toxicología Mexicana (RETOMEX). These events will be of interest to a broad range of medical and public health professionals, researchers, government professionals, and others. Register now for the 2025 ACMT Annual Scientific Meeting and Symposia. The American College of Medical Toxicology (ACMT) is a professional, nonprofit association of physicians with recognized expertise and board certification in medical toxicology. Our members specialize in the prevention, evaluation, treatment, and monitoring of injury and illness from exposures to drugs and chemicals, as well as biological and radiological agents. ACMT members work in clinical, academic, governmental, and public health settings, and provide poison control center leadership. Attachments 2025 ACMT Annual Scientific Meeting 2025 ACMT Annual Scientific Meeting and Symposia #ACMT2025
Israeli troops stormed one of the last hospitals operating in northern Gaza on Friday, igniting fires and forcing many staff and patients outside to strip in winter weather, the territory’s health ministry said. Kamal Adwan Hospital has been hit multiple times over the past three months by Israeli troops waging an offensive against Hamas fighters in surrounding neighborhoods, according to staff. The ministry said a strike on the hospital a day earlier killed five medical staff. Israel’s military said it was conducting operations against Hamas infrastructure and militants in the area of the hospital, without details. It repeated claims that Hamas fighters operate inside Kamal Adwan but provided no evidence. Hospital officials have denied that. The Health Ministry said troops forced medical personnel and patients to assemble in the yard and remove their clothes. Some were led to an unknown location, while some patients were sent to the nearby Indonesian Hospital, which was knocked out of operation after an Israel raid this week. Israeli troops during raids frequently carry out mass detentions, stripping men to their underwear for questioning in what the military says is a security measure as they search for Hamas fighters. The Associated Press doesn’t have access to Kamal Adwan, but armed plainclothes members of the Hamas-led police forces — tasked with keeping security and officially separate from the group’s armed wing — have been seen in other hospitals. The Health Ministry said Israeli troops also set fires in several parts of Kamal Adwan, including the lab and surgery department. It said 25 patients and 60 health workers remained in the hospital out of 75 patients and 180 staff who had been there. The account could not be independently confirmed, and attempts to reach hospital staff were unsuccessful. “Fire is ablaze everywhere in the hospital,” an unidentified member of the staff said in an audio message posted on the social media accounts of hospital director Hossam Abu Safiya. The staffer said some evacuated patients had been unhooked from oxygen. “There are currently patients who could die at any moment,” she said. A largely isolated north Since October, Israel’s offensive has virtually sealed off the northern Gaza areas of Jabaliya, Beit Hanoun and Beit Lahiya and leveled large parts of them. Tens of thousands of Palestinians were forced out but thousands are believed to remain in the area, where Kamal Adwan and two other hospitals are located. Troops raided Kamal Adwan in October, and on Tuesday troops stormed and evacuated the Indonesian Hospital. The area has been cut off from food and other aid for months , raising fears of famine. The U.N. says Israeli troops allowed just four humanitarian deliveries to the area from Dec. 1 to Dec. 23. The Israeli rights group Physicians for Human Rights-Israel this week petitioned Israel’s High Court of Justice seeking a halt to military attacks on Kamal Adwan. It warned that forcibly evacuating the hospital would “abandon thousands of residents in northern Gaza.” Before the latest deaths Thursday, the group documented five other staffers killed by Israeli fire since October. Israel launched its campaign in Gaza vowing to destroy Hamas after the group’s Oct. 7, 2023, attack on southern Israel in which militants killed around 1,200 people and abducted some 250 others. Around 100 Israelis remain captive in Gaza, around a third believed to be dead. Israel’s nearly 15-month-old campaign of bombardment and offensives has devastated the territory’s health sector. A year ago, it carried out raids on hospitals in northern Gaza, including Kamal Adwan, Indonesian and al-Awda Hospital, saying they served as bases for Hamas, though it presented little evidence. Israel’s campaign has killed more than 45,400 Palestinians, more than half of them women and children, and wounded more than 108,000 others, according to the Health Ministry. Its count does not distinguish between civilians and combatants. Deaths from the cold in Gaza More than 90% of Gaza’s 2.3 million Palestinians have been driven from their homes, most of them now sheltering in sprawling, squalid tent camps in south and central Gaza. Children and adults, many barefoot, huddled Friday on the cold sand in tents whose plastic and cloth sheets whipped in the wind. Overnight temperatures can dip into the 40s Fahrenheit (below 10 Celsius), and sea spray from the Mediterranean can dampen tents just steps away. “I swear to God, their mother and I cover ourselves with one blanket and we cover (their five children) with three blankets that we got from neighbors. Sea waters drowned everything that was ours,” said Muhammad al-Sous, displaced from Beit Lahiya in the north. The children collect plastic bottles to make fires, and pile under the blankets when their only set of clothes is washed and dried in the wind. At least three babies in Gaza have died from exposure to cold in recent days, doctors there have said.
TORONTO, ON / ACCESSWIRE / December 27, 2024 / SPETZ INC. (the "Company" or "Spetz") (CSE:SPTZ)(OTC Pink:DBKSF) is pleased to announce that it is arranging a private placement offering (the "Offering") of up to 5,000,000 Common Shares, at a price of $0.10 per share, for gross proceeds of up to $500,000. In addition, Spetz is proposing to settle an aggregate of $445,645.89 in accounts payable to arm's length parties by way of the issuance of 4,456,458 shares for debt at an issue price of 0.10 per share (the "Shares for Debt Transactions"), and is negotiating the restructuring of certain outstanding debt, in the aggregate principal amount of $1,017,673, consisting primarily of convertible debentures that have become due, as further described below (the "New Debentures"). The Company has been working on the foregoing initiatives for the past several weeks and believes that they are in the best interests of the Company. The Offering Spetz intends to close the Offering shortly. The proceeds from the Offering will be used for general working capital purposes and to seek additional business opportunities that will create value. Spetz does not anticipate any insider participation in the Offering, or the creation of a new insider or control person as a result of the closing of the Offering. No finder's fees or other compensation will be paid in connection with the Offering. Shares for Debt Transactions The Company is proposing to settle an aggregate of $445,645.89 of current payables to arm's length parties by the proposed issuance of a total of 4,456,458 shares, at an issue price of $0.10 per share. Spetz does not anticipate the creation of a new insider or control person as a result of the closing of the Shares for Debt Transactions. The closing of the Shares for Debt Transactions is anticipated to close concurrently with the Offering. New Debentures Spetz is working to issue new convertible debentures in the aggregate principal amount of $1,017,673, replacing primarily the principal amount of outstanding convertible debentures that have matured and are currently due and payable by Spetz. The principal amount of the new debentures would be convertible into units of the Company ("Units"), at a price per Unit of $0.20, with each Unit comprised of one (1) Common Share and one-half (1/2) of a common share purchase warrant ("Warrant"). Each whole Warrant would be exercisable for one Common Share, at a price of $0.40 per share, for a period of 24 months following the issuance of the Warrants. The New Debentures would be outstanding for a minimum of 18 months following the closing in order to allow Spetz to execute its business. Otherwise, the New Debentures would be unsecured obligations of the Company and bear interest at a rate of 12% per annum. Assuming conversion of the entire principal amount of the New Debentures, the Company would issue an aggregate of up to 5,088,365 Common Shares and up to 2,544,182 Warrants. The Company believes that the Offering, the Shares for Debt Transactions and the New Debentures are in the best interests of the Company, and the foregoing have been approved by the independent directors of the Company as well due to the fact that the completion of the proposed transactions, taken as a whole, would result in the issuance of more than 100% of the currently issued and outstanding Common Shares of Spetz, on a fully-diluted basis. Accordingly, as a result of the potential significant dilution of the Common Shares, the Company intends to issue the securities contemplated in the Offering, the Shares for Debt Transactions and the New Debentures without securityholder approval in reliance on the exceptions outlined in Section 4.6(2)(b) of CSE Policy 4, as the Company is in serious financial difficulty. The Company has explored several avenues to secure additional funding in order to continue ongoing operations and to service its outstanding debt obligations. To date, the Company has been unable to secure any such funding due to challenging capital markets conditions for venture issuers and the Company's current debt obligations. The Company recently secured some interim relief (see press release dated November 29, 2024) wherein the board of directors waived their compensation and the current holders of the outstanding secured debentures agreed to extend the maturity date from October 31, 2024 to December 31, 2024. The Company currently does not have sufficient funding to continue as a going concern, and therefore, if the proposed Offering, the Shares for Debt Transactions and the New Debentures are not completed, and no alternative arrangements are secured, there is significant doubt about the Company's ability to continue as a going concern. The Company's independent directors have also determined that the Offering, the Shares for Debt Transactions and the New Debentures are in the best interests of the Company and reasonable based on the Company's current financial circumstances in order keep the Company solvent. The Company's independent directors have determined that neither (i) seeking shareholder approval for the Offering, the Shares for Debt Transactions and the New Debentures nor (ii) a rights offering to existing securityholders on the same terms as the Offering would be feasible to complete, based on the Company's immediate liquidity requirements. All securities issued pursuant to the Offering, the Shares for Debt Transactions and the New Debentures will be subject to a statutory hold period expiring four months and one day after the closing of the Offering, the Shares for Debt Transactions and the New Debentures, respectively. Completion of the Offering, the Shares for Debt Transactions and the New Debentures is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals, including approval of the Canadian Securities Exchange. None of the securities issued in the Offering, the Shares for Debt Transactions or the New Debentures will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful. About Spetz Inc. Spetz Inc. is a multinational technology company that operates Spetz, a global online, AI-powered marketplace platform that dynamically connects consumers to nearby top-rated service providers in around 30 seconds. Spetz is available in the USA, United Kingdom, Australia, and Israel. The Spetz vision is to reinvent how people around the world connect to services in their moment of need. Connecting them immediately with the top-matched service provider for any need, anytime, anywhere. Spetz Website: www.spetz.app Spetz Investor information: https://investor.spetz.app/ Company Contacts: Investor Relations Email: Investors@spetz.app Phone: 647-956-6033 NEITHER THE CANADIAN SECURITIES EXCHANGE, NOR THEIR REGULATION SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary Note Regarding Forward-looking Statements Certain information herein constitutes "forward-looking information" as defined under Canadian securities laws, which reflect management's expectations regarding objectives, plans, goals, strategies, future growth, results of operations, performance, business prospects and opportunities of the Company. The words "plans", "expects", "does not expect", "scheduled", "estimates", "intends", "anticipates", "does not anticipate", "projects", "believes", or variations of such words and phrases or statements to the effect that certain actions, events or results "may", "will", "could", "would", "might", "occur", "be achieved", or "continue" and similar expressions identify forward-looking statements. Such forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable by management as of the date hereof, are inherently subject to significant business, economic and competitive uncertainties and contingencies. When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved. A number of factors could cause actual results to differ, possibly materially, from the results discussed in the forward-looking statements. SOURCE: Spetz Inc. View the original on accesswire.comCanucks announce injured Filip Hronek out for 8 weeks
How Ainsley Earhardt Became Fox’s Morning Queen–and Made Sean Hannity Husband No. 3It’s Friday, December 13, and the Washington Wizards (3-19) and the Cleveland Cavaliers (21-4) are all set to square off from Rocket Mortgage Field House in Cleveland. The Wizards are currently 1-9 on the road with a point differential of -16, while the Cavaliers have a 9-1 record in their last ten games at home. We’ve got all the info and analysis you need to know ahead of the game, including the latest info on the how to catch tipoff, odds, recent team performance, player stats, and of course, our predictions, picks & best bets for the game from our modeling tools and staff of experts. Listen to the Rotoworld Basketball Show for the latest fantasy player news, waiver claims, roster advice and more from our experts all season long. Click here or download it wherever you get your podcasts. Game details & how to watch Wizards vs. Cavaliers live today Date: Friday, December 13, 2024 Time: 7 pm EST Site: Rocket Mortgage Field House City: Cleveland, OH Never miss a second of the action and stay up to date with all the latest team stats and player news. Check out our day-by-day NBA schedule page , along with detailed matchup pages that update live in-game with every out. Game odds for Wizards vs. Cavaliers The latest odds as of Friday: Odds: Washington Wizards (+1018), Cleveland Cavaliers (-1923) Spread: Cavaliers -17 Over/Under: 230.5 points That gives the Wizards an implied team point total of 114.49, and the Cavaliers 123.33. Want to know which sportsbook is offering the best lines for every game on the NBA calendar? Check out the NBC Sports’ Live Odds tool to get all the latest updated info from DraftKings, FanDuel, BetMGM & more. Expert picks & predictions for Friday’s Wizards vs. Cavaliers game Please bet responsibly. If you or someone you know has a gambling problem, call the National Gambling Helpline at 1-800-522-4700. NBC Sports Bet Best Bet Brad Thomas’ (@MrBradThomas) top play: Cleveland -24.5 (+195) “The two teams have met twice already this season, and the Cavs have won both by more than 28 points. Injuries have plagued an already inexperienced and youthful Wizards team. With an avg MOV of +17, there’s more value in taking the blowout spread over the -17.5 at -110.” Our model calculates projections around each moneyline, spread and over/under bet for every game on the NBA calendar based on data points like recent performance, head-to-head player matchups, trends information and projected game totals. Once the model is finished running, we put its projections next to the latest betting lines for the game to arrive at a relative confidence level for each wager. Here are the best bets our model is projecting for today’s Wizards & Cavaliers game: Moneyline: NBC Sports Bet is staying away from a play on the Moneyline. Spread: NBC Sports Bet is leaning towards a play ATS on the Washington Wizards at -17. Total: NBC Sports Bet is leaning towards a play on the under on the Game Total of 230.5. Want even more NBA best bets and predictions from our expert staff & tools? Check out the Expert NBA Predictions page from NBC Sports for money line, spread and over/under picks for every game on today’s calendar! Important stats, trends & insights to know ahead of Wizards vs. Cavaliers on Friday The Cavaliers have won 17 of their last 20 games at home The Under is 4-1 in the Cavaliers’ last 5 matchups against Eastern Conference teams The Cavaliers have won 17 of their last 20 games at home, while the Wizards have lost on 9 straight road trips If you’re looking for more key trends and stats around the spread, moneyline and total for every single game on the schedule today, check out our NBA Top Trends tool on NBC Sports! Bet the Edge is your source for all things sports betting. Get all of Jay Croucher and Drew Dinsick’s insight weekdays at 6AM ET right here or wherever you get your favorite podcasts. Follow our experts on socials to keep up with all the latest content from the staff: - Jay Croucher (@croucherJD) - Drew Dinsick (@whale_capper) - Vaughn Dalzell (@VmoneySports) - Brad Thomas (@MrBradThomas)
Farage: Badenoch must apologise for ‘crazy conspiracy theory’ on Reform numbersMOUNTAIN VIEW, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced completion of enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS® System for the treatment of Lennox-Gastaut Syndrome (LGS), a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury. The IDE study uses the RNS System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to evaluate whether brain-responsive neurostimulation can also be used to treat LGS. NeuroPace received a $9.3 million National Institutes of Health (NIH) grant through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative to evaluate its responsive neuromodulation technology in those who suffer from LGS. The IDE study funded by the grant was conducted at six sites and enrolled a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures. The study will evaluate the safety and effectiveness of the RNS System in treating seizures associated with LGS. “We are pleased to announce the advancement of our LGS IDE study and look forward to the data and learnings it provides. The results from this study could support further research of RNS therapy to improve the treatment of people with LGS. We appreciate the dedicated efforts of the investigators, research teams, participants and their families,” said Martha Morrell, MD, Chief Medical Officer of NeuroPace. “After completing the one-year open label period, participants will transition to the long-term follow-up period, which will continue over the next 18 months.” "LGS is a devastating, childhood-onset seizure disorder that leads to lifelong disability. 85% of those with LGS continue to have seizures into adulthood despite aggressive treatment, 98% suffer from intellectual disability, and they are 12 times more likely to die prematurely than others their age," said Tracy Dixon-Salazar, PhD, Executive Director of the LGS Foundation and mother of an adult living with LGS. "LGS families desperately need innovative treatment options to manage their seizures, and we are excited about this new study." Disclaimer: Research reported in this press release was supported by the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative under award number UH3NS109557. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About the RNS® System The RNS® System, a paradigm-shifting treatment for drug-resistant focal epilepsy, is the only brain-responsive neuromodulation system approved by the FDA. The closed-loop technology delivers personalized, data-driven treatment targeted to the seizure source by continuously monitoring brain activity, recognizing a patient’s unique seizure pattern, and responding in real-time with imperceptible stimulation to prevent seizures. By recording ongoing EEG data, the RNS System provides physicians with a unique “window to the brain,” enabling them to remotely monitor their patients, gain insights based on brain activity, and use that information to optimize patient care. Long-term clinical studies demonstrate that the RNS System provides significant reduction in seizure frequency and enduring improvements in quality of life and cognition with no stimulation-related side effects. The RNS System is available at most comprehensive epilepsy centers in the United States and is widely covered by insurance. It is currently approved in the United States as an adjunctive therapy for patients 18 years of age and older with drug-resistant focal epilepsy. See full indication for use and important safety information at www.neuropace.com/safety/ . About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace’s RNS System and other important factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 12 , 2024, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace. Investor Contact: Jeremy Feffer Managing Director LifeSci Advisors jfeffer@lifesciadvisors.com